1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
EpiCast Report: Bladder Cancer - Epidemiology Forecast to 2025

EpiCast Report: Bladder Cancer - Epidemiology Forecast to 2025

  • December 2016
  • 40 pages
  • ID: 4612706
In this report:
In 2015, the ##MM had ##,## five-year diagnosed prevalent cases of bladder cancer and GlobalData epidemiologists forecast that by 2025, this number will grow to ##,##,## five-year diagnosed prevalent cases at an Annual Growth Rate (AGR) of ##.##%.
GlobalData epidemiologists forecast that by 2025, the ##MM are expected to have ##,## diagnosed incident cases of bladder cancer, representing a ##.##% increase from the number of incident cases in 2015 (##,## incident cases).

Summary

Table of Contents

Search Inside

EpiCast Report: Bladder Cancer - Epidemiology Forecast to 2025

Brief

Bladder cancer is a commonly diagnosed cancer and causes meaningful numbers of cancer deaths worldwide (Parkin, 2008; Ploeg et al., 2009). The main risk factors for bladder cancer are exposure to smoking and occupational risk factors including exposure to aromatic amines. These risk factors are more prevalent among men, which makes the disease significantly more common in men than women (Ploeg et al., 2009). The majority of bladder cancer cases are among older individuals, with the median age at diagnosis being 73 years; because of this, the comorbidities combined with bladder cancer are similar to conditions typically occurring in older age, and therefore are not particular to bladder cancer (Prout et al., 2005).

By 2025, the 7MM are anticipated to have 289,623 diagnosed incident cases of bladder cancer, representing a 23.50 percent increase from the number of incident cases in 2015 (234,581 incident cases). In 2015, the 7MM had 873,493 5-year diagnosed prevalent cases of bladder cancer and epidemiologists forecast that by 2025, this number will grow to 1,094,707 5-year diagnosed prevalent cases at an Annual Growth Rate of ~2.5 percent.

This forecast is supported by at least 10 years of historical data obtained from country-specific studies edited by the World Health Organization's International Agency for Research on Cancer, the National Cancer Institute's Surveillance, Epidemiology, and End Results program, the European Cancer Registry's fifth database registry (EUROCARE-5), the Center for Cancer Control and Information Services, National Cancer Center in Japan (JP), as well as country-specific cancer registries. The IARC's Cancer Incidence in Five Continents (CI5)plus info are the gold standard for country-level comparable analysis and were used to provide in-depth case segmentation for each country by age and sex.

The market research "EpiCast Report: Bladder Cancer - Epidemiology Forecast to 2025" provide an overview of the risk factors and overall trends of bladder cancer in the 7MM (US, France (FR), Germany (DE), Italy (IT), Spain (ES), UK, and Japan (JP)). It includes a 10-year epidemiological forecast for the diagnosed incident cases of bladder cancer divided by sex, age (beginning at 15 years and ending at =75 years), and cancer stage at diagnosis (Ta, Tis, T1, T2, T3, and T4), additionally to 5-year diagnosed prevalent cases in these seven markets.

Overview

- The Bladder Cancer EpiCast Report offers an overview of the risk factors and overall trends of bladder cancer in the 7MM (US, France (FR), Germany (DE), Italy (IT), Spain (ES), UK, and Japan (JP)). It includes a 10-year epidemiological forecast for the diagnosed incident cases of bladder cancer broken down by sex, age (beginning at 15 years and ending at =75 years), and cancer stage at diagnosis (stage 0, stage I, stage II, stage III, and stage IV), moreover to 5-year diagnosed prevalent cases in these seven markets.

- The bladder cancer epidemiology report is written and developed by Masters- and PhD-level epidemiologists.

- The EpiCast Report is detailed, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Great reasons to purchase

The Bladder Cancer EpiCast report will allow you to -

- Develop strategic management by understanding the trends shaping and driving the overall bladder cancer market.

- Quantify patient populations in the overall bladder cancer market to improve product design, pricing, and launch plans.

- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for bladder cancer therapeutics in each of the markets covered.

- Identify the percentage of bladder cancer diagnosed incident cases by stage.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Non Muscle Invasive Bladder Cancer R&D Pipeline Analysis Report, H2-2018

Non Muscle Invasive Bladder Cancer R&D Pipeline Analysis Report, H2-2018

  • $ 2200
  • Industry report
  • August 2018
  • by VPAResearch

Comprehensive Pipeline Review on Ongoing Clinical and Pre-clinical studiesNon Muscle Invasive Bladder Cancer Drug Development Pipeline Study is the latest publication from VPA Research with comprehensive ...

Muscle Invasive Bladder Cancer R&D Pipeline Analysis Report, H2-2018

Muscle Invasive Bladder Cancer R&D Pipeline Analysis Report, H2-2018

  • $ 2200
  • Industry report
  • August 2018
  • by VPAResearch

Comprehensive Pipeline Review on Ongoing Clinical and Pre-clinical studiesMuscle Invasive Bladder Cancer Drug Development Pipeline Study is the latest publication from VPA Research with comprehensive information ...

Global Bladder Cancer Partnering 2012 to 2018

Global Bladder Cancer Partnering 2012 to 2018

  • $ 1995
  • Industry report
  • October 2018
  • by Currentpartnering

The Global Bladder Cancer Partnering since 2012 report provides understanding and access to partnering deals and agreements entered into by the world’s leading healthcare companies.• Trends in partnering ...


ref:plp2016

Reportlinker.com © Copyright 2018. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on